Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin

New England Journal of Medicine

Volumn 339, Issue 27, 1998, Pages 2023-

  Sklar, Allan H ^a   Narsipur, Sri ^b  

^a United Health Services Hospitals   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN; RECOMBINANT ERYTHROPOIETIN;

DRUG EFFECT; HEART DISEASE; HEMATOCRIT; HEMODIALYSIS; HUMAN; LETTER; NORMAL VALUE; OUTCOMES RESEARCH; PRIORITY JOURNAL; COMORBIDITY; DRUG RESISTANCE; MORTALITY; NOTE; RENAL REPLACEMENT THERAPY; RISK FACTOR; EXTRACELLULAR SPACE; PATHOPHYSIOLOGY; PLASMA VOLUME;

COMORBIDITY; DRUG RESISTANCE; EPOETIN ALFA; HEART DISEASES; HEMATOCRIT; HUMANS; RENAL DIALYSIS; RISK FACTORS; EXTRACELLULAR SPACE; PLASMA VOLUME;

EID: 0032585561     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199812313392713     Document Type: Article

References (2)

1. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
2. NKF-DOQI guidelines. Anemia of chronic renal failure. V. Inadequate epoetin response. (Guidelines 20-22.) New York: National Kidney Foundation, 1997.